You just read:

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

News provided by

BerGenBio ASA

Apr 02, 2019, 01:11 ET